Context Therapeutics Inc. 8-K

What Happened

• Context Therapeutics Inc. announced on January 8, 2026 that it updated its corporate presentation for use in meetings with investors, analysts and others. The updated presentation was filed with the SEC as Exhibit 99.1 to the Current Report on Form 8‑K.
• The Form 8‑K (Regulation FD disclosure, Item 7.01) was signed by CEO Martin A. Lehr.

Key Details

• Filing date: January 8, 2026 (Form 8‑K).
• Disclosure type: Regulation FD — updated corporate presentation for investor/analyst meetings.
• Exhibit: 99.1 — Context Therapeutics Inc. Corporate Presentation, January 2026.
• Report signed by: Martin A. Lehr, Chief Executive Officer.

Why It Matters

• The 8‑K makes the company’s updated investor presentation publicly available, which may include refreshed information about strategy, pipeline or milestones (the filing itself only states that a presentation was updated and does not provide its content).
• Investors should review the attached Exhibit 99.1 if they want the latest official materials Context is using in investor and analyst outreach. The filing does not report earnings, financial results, management changes, or other transaction details.